STAT+: Pharmalittle: We’re reading about a lawsuit over lab tests for meds, a Bristol myeloma drug, and more

A U.S. appeals court has reinstated a $6.7 billion lawsuit against Bristol Myers Squibb, ruling that a lower court erred in dismissing claims that the pharmaceutical company cheated former Celgene shareholders by delaying federal approval for three drugs. The decision came from a unanimous three-judge panel, which determined that UMB Bank had the legal right to act as a representative for Celgene shareholders despite a procedural issue in its appointment as a trustee. The case stems from Bristol Myers' acquisition of Celgene for $80.3 billion in 2019, during which Celgene shareholders were granted contingent value rights, entitling them to an additional $9 per share if certain conditions related to drug approvals were met. The appeals court's ruling overturned a previous dismissal of the lawsuit, allowing the case to proceed. The core of the dispute centers on whether Bristol Myers deliberately delayed the U.S. Food and Drug Administration's (FDA) approval process for three key drugs to avoid paying the extra compensation to Celgene shareholders. If proven, such actions would constitute fraud and breach of contract. The plaintiffs argue that Bristol Myers had control over the approval timelines and manipulated them to prevent triggering the financial obligations tied to the contingent value rights. The legal battle has been ongoing since the initial filing, with both sides presenting extensive evidence and arguments. The lower court had initially dismissed the case due to concerns over UMB Bank's eligibility to represent the shareholders. However, the appeals court found that the procedural flaw did not invalidate the bank's authority to serve as a trustee. This decision allows the case to move forward, potentially leading to a trial where the allegations can be thoroughly examined. The controversy involves several key players, including Bristol Myers Squibb, UMB Bank, and the former Celgene shareholders. The latter group, represented by UMB Bank, seeks compensation based on their claim that they were wronged by Bristol Myers' alleged misconduct. The FDA's role in the case is also significant, as its approval processes are central to the legal arguments presented by both parties. The outcome of this case could set a precedent for similar disputes involving corporate acquisitions and shareholder agreements. Background on the situation reveals that the acquisition of Celgene by Bristol Myers Squibb was one of the largest in the pharmaceutical industry. At the time, the deal was praised for its potential to combine two major forces in oncology research. However, the contingent value rights clause introduced a financial incentive tied directly to the speed of drug approvals, a factor that became contentious after delays occurred. The shareholders' claim hinges on the assertion that these delays were intentional rather than coincidental. Reactions from stakeholders have varied. While Bristol Myers Squibb has consistently denied wrongdoing, stating that the delays were due to standard regulatory review processes, the plaintiffs remain steadfast in their allegations. Legal experts suggest that the case could take years to resolve, given its complexity and the high stakes involved. The pharmaceutical industry, already under scrutiny for various practices, may face increased pressure to ensure transparency in such transactions. The appeals court's decision marks a pivotal moment in the legal proceedings, offering renewed hope to the plaintiffs that justice might be served. It also underscores the importance of rigorous oversight in corporate mergers and acquisitions, particularly those involving complex financial incentives tied to regulatory outcomes. With the case now proceeding, all eyes are on the upcoming developments, which could reshape the landscape of corporate accountability in the pharmaceutical sector.